Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 7.1%

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) fell 7.1% during trading on Wednesday . The stock traded as low as $11.63 and last traded at $11.68. 445,154 shares traded hands during mid-day trading, a decline of 44% from the average session volume of 791,847 shares. The stock had previously closed at $12.57.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ZNTL. Wedbush upped their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.57.

Zentalis Pharmaceuticals Stock Up 0.7 %

The stock’s 50-day moving average price is $14.08 and its 200 day moving average price is $13.85. The firm has a market capitalization of $784.82 million, a price-to-earnings ratio of -2.44 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its earnings results on Tuesday, February 27th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.09. On average, sell-side analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Insider Activity

In other news, CFO Melissa B. Epperly sold 2,573 shares of the stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $11.44, for a total value of $29,435.12. Following the completion of the sale, the chief financial officer now directly owns 451,449 shares in the company, valued at $5,164,576.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. grew its holdings in shares of Zentalis Pharmaceuticals by 132.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $36,000 after purchasing an additional 1,030 shares during the period. Quest Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter valued at about $38,000. Tower Research Capital LLC TRC grew its holdings in shares of Zentalis Pharmaceuticals by 252.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares during the period. Exchange Traded Concepts LLC boosted its stake in Zentalis Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock worth $91,000 after buying an additional 1,519 shares during the period. Finally, OneAscent Financial Services LLC purchased a new position in Zentalis Pharmaceuticals during the fourth quarter worth about $156,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.